Research And Analysis Of The Application Of Apatinib Combined With Paclitaxel Application In The Treatment Of Non-squaous Non Small Cell Lung Cancer’s Clinical Effect

Objective:An important target for the treatment of VEGFR-2 for anti angiogenesis,apatinib as novel VEGFR-2 inhibitors,as the core of the project of the research and analysis of the application of apatinib alone contrast apatinib combined with paclitaxel application in the treatment of advanced non-squaous non small cell lung cancer’s clinical effect.Method:Fifty-four patients with advanced non-squaous and non small cell lung cancer admitted to a hospital from January 2016 to October 2017 were selected as the subjects of this study.They were randomly divided into control group and observation group.Control group: single application of paclitaxel treatment,observation group: Apatinib combined with paclitaxel treatment,27 patients in each group.The two groups were treated for at least four cycles.DCR was the main endpoint of the study.The short-term clinical efficacy and the incidence of adverse reactions were compared between the two groups,and the single and multiple factors affecting the prognosis of patients in apatinib combined with paclitaxel group were analyzed.Result:In the observation group,19 patients were effective,the effective rate was70.37%.There were 8 effective patients in the control group,the effective rate was29.63%.The effective rate of the observation group was significantly higher than that of the control group,with statistical significance(P < 0.05).There were significant differences in the incidence of proteinuria and hypertension between the observation group and the control group(P < 0.05).There were significant differences in bone marrow suppression,digestive tract reaction,hand-foot syndrome and other adverse reactions(P > 0.05).ORR comparison of two groups: observation group 11.11% vs control group 3.70%,P = 0.603,no statistical difference.Tumor staging,ECOG score and adverse reactions were the single factors affecting the prognosis of patients treated with apatinib combined with paclitaxel.The above three factors were independent risk factors for the prognosis of patients treated with apatinib combined with paclitaxel in advanced non-squaous non small cell lung cancer.Conclusion:1.The short-term efficacy of apatinib and combination chemotherapy is better than that of paclitaxel alone in the treatment of advanced non-squaous non small cell lung cancer.2.The adverse reactions of hypertension and proteinuria in the combined drug group were significantly higher than those in the single drug group,with statistical significance,but the adverse reactions were within the scope of control.Some serious adverse reactions were significantly alleviated after drug reduction,and no deaths due to adverse reactions were reported.3.For the observation group,the differentiation of tumor tissue,ECOG score and adverse reactions after treatment are directly related to their prognosis.The patients with high differentiation and ECOG score of 0-1 and adverse reactions of less than 2 have better prognosis.In addition,all the factors involved in this study will not have a direct impact on the prognosis of patients.